Protara Therapeutics, Inc. (TARA) Debt-to-equity % [USD] 2015 - 2024

Historical data

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Protara Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from 2015 to 2024.
  • Protara Therapeutics, Inc. Debt-to-equity for the quarter ending March 31, 2024 was 14.5 %, a 67.1% increase year-over-year.
Debt-to-equity, Quarterly (% [USD])
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q1 2024 14.5 +5.81 +67.1% Mar 31, 2024
Q4 2023 13.4 +6.19 +85.4% Dec 31, 2023
Q3 2023 12.3 +5.89 +91.5% Sep 30, 2023
Q2 2023 10 +3.75 +59.9% Jun 30, 2023
Q1 2023 8.66 +2.55 +41.8% Mar 31, 2023
Q4 2022 7.25 +2.13 +41.6% Dec 31, 2022
Q3 2022 6.44 +2.5 +63.5% Sep 30, 2022
Q2 2022 6.26 +3.24 +107% Jun 30, 2022
Q1 2022 6.11 +3.56 +140% Mar 31, 2022
Q4 2021 5.12 +1.76 +52.5% Dec 31, 2021
Q3 2021 3.94 -1.37 -25.8% Sep 30, 2021
Q2 2021 3.02 -8.54 -73.9% Jun 30, 2021
Q1 2021 2.54 -16.6 -86.7% Mar 31, 2021
Q4 2020 3.35 -297 -98.9% Dec 31, 2020
Q3 2020 5.31 -92.7 -94.6% Sep 30, 2020
Q2 2020 11.6 -20.2 -63.6% Jun 30, 2020
Q1 2020 19.2 +0.03 +0.16% Mar 31, 2020
Q4 2019 300 +280 +1409% Dec 31, 2019
Q3 2019 98 +78 +388% Sep 30, 2019
Q2 2019 31.8 +8.87 +38.8% Jun 30, 2019
Q1 2019 19.1 -4.51 -19.1% Mar 31, 2019
Q4 2018 19.9 +1.25 +6.7% Dec 31, 2018
Q3 2018 20.1 +4.88 +32.1% Sep 30, 2018
Q2 2018 22.9 +11.1 +93.6% Jun 30, 2018
Q1 2018 23.6 +13 +122% Mar 31, 2018
Q4 2017 18.7 +9.07 +94.7% Dec 31, 2017
Q3 2017 15.2 +7.16 +89.1% Sep 30, 2017
Q2 2017 11.8 +5.3 +81.3% Jun 30, 2017
Q1 2017 10.7 +5.44 +104% Mar 31, 2017
Q4 2016 9.58 +5.07 +112% Dec 31, 2016
Q3 2016 8.04 +4.4 +121% Sep 30, 2016
Q2 2016 6.52 -12.4 -65.6% Jun 30, 2016
Q1 2016 5.22 Mar 31, 2016
Q4 2015 4.51 Dec 31, 2015
Q3 2015 3.64 Sep 30, 2015
Q2 2015 19 Jun 30, 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.